FDA declines to approve Sarepta’s second Duchenne treatment
(Reuters) – Sarepta Therapeutics Inc said on Monday the U.S. Food and Drug Administration declined to approve its newest treatment for Duchenne muscular dystrophy (DMD), citing safety concerns including the…